Armistice Capital LLC has recently announced that it has increased stake in Addex Therapeutics Ltd (NASDAQ:ADXN) by 26.47%. After grabbing 0.32 million shares, the institutional investor is now in possession of 66983.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 1.96% having worth around $0.25 million. Moreover, Renaissance Technologies LLC increased its share by 29547.0 to have a control over 29547.0 shares. And FNY Capital Management LP raised its holdings to 22500.0 shares by acquiring 22500.0 shares or 0.14% of the stake.
Addex Therapeutics Ltd (ADXN) concluded trading on 01/12/23 at a closing price of $0.84, with 0.43 million shares of worth about $0.36 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -14.29% during that period and on Thursday the price saw a gain of about 6.99%. Currently the company’s common shares owned by public are about 12.86M shares, out of which, 12.86M shares are available for trading.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 2 analysts are covering the ADXN stock and their offered price forecasts bring an average price target of $1.01. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $1.01 and could fall to a lowest price of $1.01. However, touching the estimated high of $1.01 would mean a gain of 16.83% for the stock.
Addex Therapeutics Ltd (NASDAQ: ADXN) started trading at $0.7693, below -$0.02 from concluding price of the previous day. However, the stock later moved at a day high price of 0.8475, or with a gain of 6.99%. Stock saw a price change of 13.12% in past 5 days and over the past one month there was a price change of 31.35%. Year-to-date (YTD), ADXN shares are showing a performance of 33.31% which decreased to -86.65% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.55 but also hit the highest price of $6.55 during that period. The average intraday trading volume for Addex Therapeutics Ltd shares is 148.94K. The stock is currently trading 29.29% above its 20-day simple moving average (SMA20), while that difference is up 16.97% for SMA50 and it goes to -55.50% lower than SMA200.
Armistice Capital LLC acquired 0.32 million shares of Addex Therapeutics Ltd having value of about $0.25 million. Data submitted at the U.S SEC by Armistice Capital LLC revealed that the firm now holds 66983.0 shares in the company valued at close to $56265.72, or have control over 26.47% stake in the company. Addex Therapeutics Ltd (NASDAQ: ADXN) currently have 12.86M outstanding shares and institutions hold larger chunk of about 47.62% of that. Holding of mutual funds in the company is about — while other institutional holders and individual stake holders have control over — and — of the stake respectively.
The stock has a current market capitalization of $18.37M. It has posted earnings per share of -$3.26 in the same period. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ADXN, volatility over the week remained 10.95% while standing at 10.18% over the month.
Analysts at 2 brokerage firms have issued recommendations for the Addex Therapeutics Ltd (ADXN)’s stock out of those 2 Wall Street analysts, 0 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 1 analyst recommended the stock as “Sell”.
